Kapp, Friedrich G.
Perlin, Julie R.
Hagedorn, Elliott J.
Gansner, John M.
Schwarz, Daniel E.
O’Connell, Lauren A.
Johnson, Nicholas S.
Amemiya, Chris
Fisher, David E.
Wölfle, Ute
Trompouki, Eirini
Niemeyer, Charlotte M.
Driever, Wolfgang
Zon, Leonard I.
Article History
Received: 3 July 2017
Accepted: 15 May 2018
First Online: 13 June 2018
Competing interests
: L.I.Z. is a founder and stockholder of Fate Therapeutics, Inc., Scholar Rock and Camp4 Therapeutics. D.E.F. has a financial interest in Soltego, Inc., a company developing SIK inhibitors for topical skin darkening treatments that might be used for a broad set of human applications. The interests of D.E.F. were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.